

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

PROFIT WARNING

This announcement is made by China Resources Medical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors of the Company (the “**Director(s)**”) wishes to inform the shareholders of the Company (the “**Shareholder(s)**”) and potential investors that the Company is in the course of preparing its consolidated financial results for the year ended December 31, 2025 (the “**Reporting Period**”). Based on the available information and a preliminary assessment of the unaudited consolidated management accounts of the Group for the Reporting Period, it is estimated that the profit attributable to owners of the Company for the Reporting Period will be approximately RMB467 million to RMB516 million, representing a decrease of approximately 17.5% to 8.9% as compared to the Group’s profit attributable to owners of the Company for the year ended December 31, 2024 (the “**Year 2024**”) of approximately RMB566 million; whereas, after excluding the one-off compensation for the management fees in previous years and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group in 2025 (the “**Yan Hua Compensation**”) and the corresponding enterprise income tax, the profit attributable to the owners of the Company would decrease by approximately 43.5% to 37.6% as compared to the Year 2024, the decrease of which was narrowed by 13.9 to 19.8 percentage points as compared to the 57.4% decrease in profit attributable to the owners of the Company (after excluding the Yan Hua Compensation) in the first half of 2025 when compared against the corresponding period in Year 2024. For further details of the Yan Hua IOT Agreement and the Yan Hua Compensation, please refer to the announcement of the Company dated February 21, 2025. The decrease in profit attributable to the owners of the Company for the Reporting Period is mainly attributable to the decrease in operating profits of member medical institutions caused by a decrease in average medical insurance fee per visit, and the scaling back of the IOT (the “invest-operate-transfer” model) business of the Company.

Since the second half of 2025, the Company continued to proactively improve the revenue structure, promote management refinement and control operating costs in order to increase operating performance. The revenue and number of patient visits for the second half of 2025 were both increased as compared with that of the first half of 2025. The bank borrowings of the Company in 2025 have decreased by approximately RMB780 million compared with that at the end of 2024, the interest-bearing debt ratio has further decreased, and the Company had sufficient cash flow. In 2025, the Company simultaneously and actively responded to changes in the external environment by strengthening its foundation in comprehensive medical care, and proactively explored intelligent healthcare services. The revenue from healthcare management in 2025 has accordingly increased compared to 2024. Apart from the ongoing healthcare management businesses by the hospitals, the Company also expanded into full-cycle health services, which included the set up of the “Runxin healthcare hut” at the China Resources Tower in Shenzhen providing on-site services for enterprises; and explored innovative services including “doctors in the neighborhood”, “internet+in-home nursing” etc. in certain regions for extending household services, in order to establish a practical foundation for the construction of a full-cycle intelligent health services model.

The Company is still in the process of finalising the Group’s consolidated financial results for the Reporting Period. The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment with reference to the unaudited consolidated management accounts of the Group for the Reporting Period, which are yet to be reviewed by the audit committee of the Company nor audited by the auditors of the Company.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company and are advised to refer to the details in the annual results announcement for the Reporting Period to be published by the Company before the end of March 2026.

By order of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, February 27, 2026

As at the date of this announcement, the Board comprises Mr. YU Hai, Mr. ZHANG Chuang, Mr. WANG Yuexing and Mr. WU Xinchun as executive Directors; Ms. GE Lu as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.